74 related articles for article (PubMed ID: 10466787)
1. Site-saturation mutagenesis of the PALTAVETG motif in coxsackievirus A9 capsid protein VP1 reveals evidence of conservation of a periodic hydrophobicity profile.
Airaksinen A; Roivainen M; Stanway G; Hovi T
J Gen Virol; 1999 Aug; 80 ( Pt 8)():1919-1927. PubMed ID: 10466787
[TBL] [Abstract][Full Text] [Related]
2. The nucleotide sequences of wild-type coxsackievirus A9 strains imply that an RGD motif in VP1 is functionally significant.
Chang KH; Day C; Walker J; Hyypiä T; Stanway G
J Gen Virol; 1992 Mar; 73 ( Pt 3)():621-6. PubMed ID: 1312121
[TBL] [Abstract][Full Text] [Related]
3. Coxsackievirus A9 VP1 mutants with enhanced or hindered A particle formation and decreased infectivity.
Airaksinen A; Roivainen M; Hovi T
J Virol; 2001 Jan; 75(2):952-60. PubMed ID: 11134308
[TBL] [Abstract][Full Text] [Related]
4. Foot-and-mouth disease virus can utilize the C-terminal extension of coxsackievirus A9 VP1 for cell infection.
Leippert M; Pfaff E
J Gen Virol; 2001 Jul; 82(Pt 7):1703-1711. PubMed ID: 11413382
[TBL] [Abstract][Full Text] [Related]
5. The nucleotide sequence of coxsackievirus A9; implications for receptor binding and enterovirus classification.
Chang KH; Auvinen P; Hyypiä T; Stanway G
J Gen Virol; 1989 Dec; 70 ( Pt 12)():3269-80. PubMed ID: 2558158
[TBL] [Abstract][Full Text] [Related]
6. The coxsackievirus A9 RGD motif is not essential for virus viability.
Hughes PJ; Horsnell C; Hyypiä T; Stanway G
J Virol; 1995 Dec; 69(12):8035-40. PubMed ID: 7494317
[TBL] [Abstract][Full Text] [Related]
7. Susceptibility of coxsackievirus B3 laboratory strains and clinical isolates to the capsid function inhibitor pleconaril: antiviral studies with virus chimeras demonstrate the crucial role of amino acid 1092 in treatment.
Schmidtke M; Hammerschmidt E; Schüler S; Zell R; Birch-Hirschfeld E; Makarov VA; Riabova OB; Wutzler P
J Antimicrob Chemother; 2005 Oct; 56(4):648-56. PubMed ID: 16150864
[TBL] [Abstract][Full Text] [Related]
8. RGD-dependent entry of coxsackievirus A9 into host cells and its bypass after cleavage of VP1 protein by intestinal proteases.
Roivainen M; Hyypiä T; Piirainen L; Kalkkinen N; Stanway G; Hovi T
J Virol; 1991 Sep; 65(9):4735-40. PubMed ID: 1870199
[TBL] [Abstract][Full Text] [Related]
9. Induction of neutralizing antibodies by synthetic peptides representing the C terminus of coxsackievirus A9 capsid protein VP1.
Pulli T; Roivainen M; Hovi T; Hyypiä T
J Gen Virol; 1998 Sep; 79 ( Pt 9)():2249-53. PubMed ID: 9747735
[TBL] [Abstract][Full Text] [Related]
10. Efficient RGD-independent entry process of coxsackievirus A9.
Roivainen M; Piirainen L; Hovi T
Arch Virol; 1996; 141(10):1909-19. PubMed ID: 8920824
[TBL] [Abstract][Full Text] [Related]
11. A single-amino-acid substitution in polyomavirus VP1 correlates with plaque size and hemagglutination behavior.
Freund R; Garcea RL; Sahli R; Benjamin TL
J Virol; 1991 Jan; 65(1):350-5. PubMed ID: 1845896
[TBL] [Abstract][Full Text] [Related]
12. Mutation in enterovirus 71 capsid protein VP1 confers resistance to the inhibitory effects of pyridyl imidazolidinone.
Shih SR; Tsai MC; Tseng SN; Won KF; Shia KS; Li WT; Chern JH; Chen GW; Lee CC; Lee YC; Peng KC; Chao YS
Antimicrob Agents Chemother; 2004 Sep; 48(9):3523-9. PubMed ID: 15328120
[TBL] [Abstract][Full Text] [Related]
13. Molecular epidemiology of coxsackievirus B4 and disclosure of the correct VP1/2A(pro) cleavage site: evidence for high genomic diversity and long-term endemicity of distinct genotypes.
Mulders MN; Salminen M; Kalkkinen N; Hovi T
J Gen Virol; 2000 Mar; 81(Pt 3):803-12. PubMed ID: 10675418
[TBL] [Abstract][Full Text] [Related]
14. Mutational analysis of the adeno-associated virus type 2 (AAV2) capsid gene and construction of AAV2 vectors with altered tropism.
Wu P; Xiao W; Conlon T; Hughes J; Agbandje-McKenna M; Ferkol T; Flotte T; Muzyczka N
J Virol; 2000 Sep; 74(18):8635-47. PubMed ID: 10954565
[TBL] [Abstract][Full Text] [Related]
15. The crystal structure of coxsackievirus A9: new insights into the uncoating mechanisms of enteroviruses.
Hendry E; Hatanaka H; Fry E; Smyth M; Tate J; Stanway G; Santti J; Maaronen M; Hyypiä T; Stuart D
Structure; 1999 Dec; 7(12):1527-38. PubMed ID: 10647183
[TBL] [Abstract][Full Text] [Related]
16. Molecular epidemiology and evolution of coxsackievirus A9.
Santti J; Harvala H; Kinnunen L; Hyypiä T
J Gen Virol; 2000 May; 81(Pt 5):1361-72. PubMed ID: 10769080
[TBL] [Abstract][Full Text] [Related]
17. High affinity interactions of Coxsackievirus A9 with integrin alphavbeta3 (CD51/61) require the CYDMKTTC sequence of beta3, but do not require the RGD sequence of the CAV-9 VP1 protein.
Triantafilou M; Triantafilou K; Wilson KM; Takada Y; Fernandez N
Hum Immunol; 2000 May; 61(5):453-9. PubMed ID: 10773347
[TBL] [Abstract][Full Text] [Related]
18. A single amino acid substitution in the capsid protein VP1 of coxsackievirus B3 (CVB3) alters plaque phenotype in Vero cells but not cardiovirulence in a mouse model.
Zhang H; Blake NW; Ouyang X; Pandolfino YA; Morgan-Capner P; Archard LC
Arch Virol; 1995; 140(5):959-66. PubMed ID: 7605207
[TBL] [Abstract][Full Text] [Related]
19. The nucleotide sequence of the 5'non-coding and capsid coding genome regions of two bovine enterovirus strains.
McNally RM; Earle JA; McIlhatton M; Hoey EM; Martin SJ
Arch Virol; 1994; 139(3-4):287-99. PubMed ID: 7832636
[TBL] [Abstract][Full Text] [Related]
20. Birnavirus VP1 proteins form a distinct subgroup of RNA-dependent RNA polymerases lacking a GDD motif.
Shwed PS; Dobos P; Cameron LA; Vakharia VN; Duncan R
Virology; 2002 May; 296(2):241-50. PubMed ID: 12069523
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
